Shenzhen Neptunus Interlong Bio-technique Company Limited

SEHK:8329 Stock Report

Market Cap: HK$268.5m

Shenzhen Neptunus Interlong Bio-technique Past Earnings Performance

Past criteria checks 0/6

Shenzhen Neptunus Interlong Bio-technique's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 0.7% per year. Shenzhen Neptunus Interlong Bio-technique's return on equity is 2.3%, and it has net margins of 3.1%.

Key information

-6.2%

Earnings growth rate

-6.2%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate0.7%
Return on equity2.3%
Net Margin3.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Apr 19
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Recent updates

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Nov 07
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

Sep 05
Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Apr 19
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Oct 03
These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Mar 29
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

Sep 28
We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Aug 18
A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Jun 06
Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Dec 15
Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Dec 29
Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Nov 24
Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Revenue & Expenses Breakdown

How Shenzhen Neptunus Interlong Bio-technique makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:8329 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,054322870
31 Mar 241,045273090
31 Dec 231,065243460
30 Sep 231,120643780
30 Jun 231,103643790
31 Mar 231,071603750
31 Dec 22987543410
30 Sep 22931473240
30 Jun 22886373150
31 Mar 22835313030
31 Dec 21839363210
30 Sep 21868333790
30 Jun 21963384420
31 Mar 211,056435060
31 Dec 201,031374850
30 Sep 201,077524720
30 Jun 201,065594730
31 Mar 201,059574920
31 Dec 191,081605220
30 Sep 191,006564910
30 Jun 19937524560
31 Mar 19879474170
31 Dec 18867484050
30 Sep 18862434090
30 Jun 18848433810
31 Mar 18835513520
31 Dec 17790503140
30 Sep 17803643000
30 Jun 17772642850
31 Mar 17777652820
31 Dec 16759632760
30 Sep 16738372820
30 Jun 16726292780
31 Mar 16713202700
31 Dec 15721212580
30 Sep 15664192190
30 Jun 15662231960
31 Mar 15650311730
31 Dec 14648331700
30 Sep 14633301650
30 Jun 14630271670
31 Mar 14603371560
31 Dec 13612361610

Quality Earnings: 8329 has a large one-off loss of CN¥17.9M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 8329's current net profit margins (3.1%) are lower than last year (5.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8329's earnings have declined by 6.2% per year over the past 5 years.

Accelerating Growth: 8329's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 8329 had negative earnings growth (-49.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.4%).


Return on Equity

High ROE: 8329's Return on Equity (2.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Neptunus Interlong Bio-technique Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution